Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
Kenneth N. Olivier(University of North Carolina at Chapel Hill), Richard J. Wallace(The University of Texas at Tyler), Kevin Winthrop(Oregon Health & Science University), Doreen Addrizzo‐Harris(Unknown), Matthias Salathé(University of Miami), Gina Eagle(Insmed (United States)), Keith Liu(Insmed (United States)), Liza Micioni(Insmed (United States)), Stephen J. Ruoss(National Heart Lung and Blood Institute), Daniel Dorgan(University of Pennsylvania), Charles L. Daley(National Jewish Health), Renu Gupta(Insmed (United States)), David E. Griffith(National Jewish Health), Barbara A. Brown‐Elliott(The University of Texas Health Science Center at Tyler), John P. McGinnis(Insmed (United States)), Patrick A. Flume(Medical University of South Carolina)
American Journal of Respiratory and Critical Care Medicine
October 17, 2016
Cited by 246
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
|CHEST Journal|2006|1.2k